Miller Anestesia

Anestesia fuera del quirófano

2249

Sección IV

Anestesia por subespecialidades en el adulto

98. Rubin P, Soni A, Williams JP: The molecular and cellu-

lar biologic basis for the radiation treatment of benign

proliferative diseases. Semin Radiat Oncol 9:203–214,

1999.

99. Park KW: Intracoronary brachytherapy and drug-

eluting coronary stents. Int Anesthesiol Clin

43(2)91–100, 2005.

100. de-Bruijn NP, Hlatky MA, Jacobs JR, et al: General

anesthesia during percutaneous transluminal coro-

nary angioplasty for acute myocardial infarction:

Results of a randomized controlled clinical trial.

Anesth Analg 68:201–207, 1989.

101. Shawl FA, Baxley WA: Role of percutaneous cardio-

pulmonary bypass and other support devices in

interventional cardiology. Cardiol Clin 12:543–557,

1994.

102. Suarez de Lezo J, Pan M, Medina A, et al: Percuta-

neous cardiopulmonary support in critical patients

needing coronary interventions with stents. Cathet

Cardiovasc Interv 57:467–475, 2002.

103. Friedman PA, Munger TM, Torres N, Rihal C: Per-

cutaneous endocardial and epicardial ablation of

hypotensive ventricular tachycardia with percuta-

neous left ventricular assist in the electrophysiology

laboratory. J Cardiovasc Electrophysiol 18:106–109,

2007.

104. Manners JM, Codman VA: General anesthesia for

cardiac catheterization in children: The effect of spon-

taneous or controlled ventilation on the evaluation of

congenital abnormalities. Anaesthesia 24:541–553,

1969.

105. Korten K: Anesthesia for diagnostic procedures. Am

Fam Physician 15:103–107, 1977.

106. Manners JM: Anaesthesia for diagnostic procedures

in cardiac disease. Br J Anaesth 43:276–287, 1971.

107. BermanW Jr, Fripp RR, Rubler M, Alderete L: Hemo-

dynamic effects of ketamine in children undergoing

cardiac catheterization. Pediatr Cardiol 11:72–76,

1990.

108. Reich DL, Silvay G: Ketamine: An update on the first

twenty-five years of clinical experience. Can J

Anaesth 36:186–197, 1989.

109. Coppel DL, Dundee JW: Ketamine anaesthesia for

cardiac catheterization. Anaesthesia 27:25–31,

1972.

110. Faithfull NS, Haider R: Ketamine for cardiac cathe-

terization: An evaluation of its use in children.

Anaesthesia 26:318–323, 1971.

111. Lebovic S, Reich DL, Steinberg LG, et al: Compari-

son of propofol versus ketamine in pediatric patients

undergoing cardiac catheterization. Anesth Analg

74:490–494, 1992.

112. Rautiainen P: Alfentanil infusion for sedation in

infants and small children during cardiac catheteri-

zation. Can J Anaesth 38:980–984, 1991.

113. Meretoja OA, Rautiainen P: Alfentanil and fentanyl

sedation in infants and small children during

cardiac catheterization. Can J Anaesth 37:624–628,

1990.

114. Kan JS, White RI Jr, Mitchell SE, et al: Percutaneous

balloon valvuloplasty: A new method for treating

congenital pulmonary-valve stenosis. N Engl J Med

307:540–542, 1982.

115. Allen HD, Beekman RH III, Gason A Jr, et al:

Pediatric therapeutic cardiac catheterization: A

statement for healthcare professionals from the

Council on Cardiovascular Disease in the Young.

American Heart Association. Circulation 97:609–

625, 1998.

116. Cribier A, Savin T, Saoudi N, et al: Percutaneous

transluminal valvuloplasty of acquired aortic steno-

sis in elderly patients: An alternative to valve repla-

cement? Lancet 1:63–67, 1986.

117. Magee AG, Qureshi SA: Closure of atrial septal

defects by transcatheter devices. Pediatr Cardiol

18:326–327, 1997.

118. Hekmat K, Mehlhorn U, Rainer de Vivie E: Surgical

repair of a large residual atrial septal defect after

transcatheter closure. Ann Thorac Surg 63:1456–

1458, 1997.

119. Hein R, Lang K, Wunderlich N, et al: Percutaneous

closure of paravalvular leaks. J Interv Cardiol

19:S73–S77, 2006.

120. Shook DC, Gross W: Offsite anesthesiology in the

cardiac catheterization lab. Curr Opin Anesthesiol

20:352–358, 2007.

121. Sigwart U: Non surgical myocardial reduction for

hypertrophic obstructive cardiomyopathy. Lancet

346:211–213, 1995.

122. Lakkis N: New treatment methods for patients with

hypertrophic obstructive cardiomyopathy. Curr

Opin Cardiol 15:172–177, 2000.

123. SinghM,EdwardsWD,HolmesDRJr,

etal:Anatomy

of the first septal perforating artery: A study with

implications for ablation therapy for hypertrophic

cardiomyopathy. Mayo Clin Proc 76:799–802,

2001.

124. VanderheydenM, WillaertW, Claessens P: Nonalco-

holic percutaneous transluminal septal ablation for

hypertrophic cardiomyopathy with obstruction. Am

J Cardiol 89:361–362, 2002.

125. Cribier A, Elthaninoff H, Tron C, et al: Percutaneous

implantation of aortic valve prosthesis in patients

with calcific aortic stenosis: Technical advances, cli-

nical results and future strategies. J Interv Cardiol

19:S87–S96, 2007.

126. Block PC: Percutaneous transcatheter repair for

mitral regurgitation. J Interv Cardiol 19:547–551,

2006.

127. Hammill SC, Sugrue DD, Gersh BJ, et al: Clinical

intracardiac electrophysiologic testing: Technique,

diagnostic indications, and therapeutic uses. Mayo

Clin Proc 61:478–503, 1986.

128. Kutalek SP: Pacemaker and defibrillator lead extrac-

tion. Curr Opin Cardiol 19:19–22, 2004.

129. Kerber RE: Transthoracic cardioversion of atrial

fibrillation and flutter: Standard techniques and new

advances. Am J Cardiol 78(8A)22–26, 1996.

130. Sternlo JE, Hagerdal M: Anaesthesia for cardiover-

sion— clinical experiences with propofol and thio-

pentone. Acta Anaesthesiol Scand 35:606–608, 1991.

131. Canessa R, Lema G, Urzua J, et al: Anesthesia for elec-

tive cardioversion: A comparison of four anesthetic

agents. J Cardiothorac Vasc Anesth 5:566–568, 1991.

132. Ford SR, Maze M, Gaba DM: A comparison of eto-

midate and thiopental anesthesia for cardioversion.

J Cardiothorac Vasc Anesth 5:563–565, 1991.

133. Fennelly ME, Powell H, Galletly DC, Whitwam JG:

Midazolam sedation reversed with flumazenil for

cardioversion. Br J Anaesth 68:303–305, 1992.

134. Rasmussen KG, Sampson SM, Rummans TA: Elec-

troconvulsive therapy and newer modalities for the

treatment of medication-refractory mental illness.

Mayo Clin Proc 77:552–556, 2002.

135. Selvin BL: Electroconvulsive therapy—1987. Anes-

thesiology 67:367–385, 1987.

136. Walker R, Swartz CM: Electroconvulsive therapy

during high-risk pregnancy. Gen Hosp Psychiatry

16:348–353, 1994.

137. Sanacora G, Mason GF, Rothman DL, et al: Increa-

sed cortical GABA concentrations in depressed

patients receiving ECT. Am J Psychiatry 160:577–

579, 2003.

138. Rasmussen KG, Laurila DR, Brady BM, et al: Seizure

length with sevoflurane and thiopental for induc-

tion of general anesthesia in electroconvulsive

therapy: A randomized double-blind trial. J ECT

22:240–242, 2006.

139. Saito S, Miyoshi S, Yoshikawa D, et al: Regional cere-

bral oxygen saturation during electroconvulsive

therapy: Monitoring by near-infrared spectrophoto-

metry. Anesth Analg 83:726–730, 1996.

140. Wagner KJ, Mollenberg O, Rentrop M, et al: Guide

to anaesthetic selection for electroconvulsive

therapy. CNS Drugs 19:745–758, 2005.

141. Dec GW Jr, Stern TA, Welch C: The effects of elec-

troconvulsive therapy on serial electrocardiograms

and serum cardiac enzyme values. A prospective

study of depressed hospitalized inpatients. JAMA

253:2525–2529, 1985.

142. Cockey GH, Conti CR: Electroconvulsive therapy–

induced transient T-wave inversions on ECG. Clin

Cardiol 18:418–420, 1995.

143. Rice EH, Sombrotto LB, Markowitz JC, Leon AC:

Cardiovascular morbidity in high-risk patients

during ECT. Am J Psychiatry 151:1637–1641, 1994.

144. Nuttall GA, Bowersox MR, Douglass SB, et al: Mor-

bidity and mortality in the use of electroconvulsive

therapy. J ECT 20:237–241, 2004.

145. Reddy S, Nobler MS: Dangerous hyperglycemia

associated with electroconvulsive therapy. Convuls

Ther 12:99–103, 1996.

146. Janowsky EC, Risch C, Janowsky DS: Effects of anes-

thesia on patients taking psychotropic drugs. J Clin

Psychopharmacol 1:14–20, 1981.

147. Potter WZ, Rudorfer MV, Manji H: The pharmaco-

logic treatment of depression. N Engl J Med

325:633–642, 1991.

148. Pritchett JT, Bernstein HJ, Kellner CH: Combined

ECT and antidepressant drug therapy. Convuls Ther

9:256–261, 1993.

149. Naguib M, Koorn R: Interactions between psycho-

tropics, anaesthetics and electroconvulsive therapy:

Implications for drug choice and patient manage-

ment. CNS Drugs 16:229–247, 2002.

150. Mukherjee S: Combined ECT and lithium therapy.

Convuls Ther 9:274–284, 1993.

151. Folk JW, Kellner CH, Beale MD, et al: Anesthesia for

electroconvulsive therapy: A review. J ECT 16:157–

170, 2000.

152. Saito S: Anesthesia management for electroconvul-

sive therapy: Hemodynamic and respiratory mana-

gement. J Anesth 19:142–149, 2005.

153. McCormick ASM, Saunders DA: Oxygen saturation

of patients recovering from electroconvulsive

therapy. Anaesthesia 51:702–704, 1996.

154. Malsch E, Gratz I, Mani S, et al: Efficacy of electro-

convulsive therapy after propofol and methohexital

anesthesia. Convuls Ther 10:212–219, 1994.

155. Martensson B, Bartfai A, Hallen B, et al: A compari-

son of propofol and methohexital as anesthetic

agents for ECT: Effects on seizure duration, thera-

peutic outcome, and memory. Biol Psychiatry

35:179–189, 1994.

156. Fear CF, Littlejohns CS, Rouse E, McQuail P: Propo-

fol anesthesia in electroconvulsive therapy. Reduced

seizure duration may not be relevant. Br J Psychiatry

165:506–509, 1994.

157. Boey WK, Lai FO: Comparison of propofol and

thiopentone as anaesthetic agents for electroconvul-

sive therapy. Anaesthesia 45:623–628, 1990.

158. Trzepacz PT, Weniger FC, Greenhouse J: Etomidate

anesthesia increases seizure duration during ECT: A

retrospective study. Gen Hosp Psychiatry 15:115–

120, 1993.

159. Rasmussen KG, Jarvis MR, Zorumski CF: Ketamine

anesthesia in electroconvulsive therapy. Convuls

Ther 12:217–223, 1996.

160. Rasmussen KG, Laurila DR, Brady BM, et al: Anes-

thesia outcomes in a randomized double-blind trial

of sevoflurane and thiopental for induction of

general anesthesia in electroconvulsive therapy. J

ECT 23:236–238, 2007.

161. Andersen FA, Arsland D, Holt-Larsen H: Effects of

combined methohexitone-remifentanil anaesthesia

in electroconvulsive therapy. Acta Anaesthesiol

Scand 45:830–833, 2001.

162. Kelly D, Brull SJ: Neuroleptic malignant syndrome

and mivacurium: A safe alternative to succinylcho-

line? Can J Anaesth 41:845–849, 1994.

163. Fredman B, Smith I, d’Etienne J, et al: Use of muscle

relaxants for electroconvulsive therapy: How much

is enough [letter]? Anesth Analg 78:190, 1994.

164. Janis K, Hess J, Fabian JA, Gillis M: Substitution of

mivacurium for succinylcholine for ECT in elderly

patients. Can J Anaesth 42:612–613, 1995.

165. Castelli I, Steiner LA, Kaufmann MA, et al: Compa-

rative effects of esmolol and labetalol to attenuate

hyperdynamic states after electroconvulsive therapy.

Anesth Analg 80:557–561, 1995.

166. Howie MB, Black HA, Zvara D, et al: Esmolol

reduces autonomic hypersensitivity and length of

seizures induced by electroconvulsive therapy.

Anesth Analg 71:384–388, 1990.

167. Kovac AL, Goto H, Pardo MP, Arakawa K: Compa-

rison of two esmolol bolus doses on the haemody-

namic response and seizure duration during

electroconvulsive therapy. Can J Anaesth 38:204–

208, 1991.